BiotechTube

BAF312 + Placebo

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Secondary Progressive Multiple Sclerosis

Conditions

Secondary Progressive Multiple Sclerosis

Trial Timeline

Dec 20, 2012 → Mar 31, 2023

NCT ID
NCT01665144

About BAF312 + Placebo

BAF312 + Placebo is a phase 3 stage product being developed by Novartis for Secondary Progressive Multiple Sclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01665144. Target conditions include Secondary Progressive Multiple Sclerosis.

What happened to similar drugs?

13 of 20 similar drugs in Secondary Progressive Multiple Sclerosis were approved

Approved (13) Terminated (0) Active (7)
✅Cinacalcet HClKyowa KirinApproved
✅Paricalcitol + CalcifediolAbbVieApproved
✅Paricalcitol + Darbepoetin alfaAbbVieApproved
✅RanibizumabNovartisApproved
✅BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273NovartisApproved
✅RanibizumabNovartisApproved
✅Sensipar® + Vitamin DAmgenApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT02029274Phase 2Terminated
NCT01665144Phase 3Completed
NCT01148810Phase 2Terminated
NCT00879658Phase 2Completed

Competing Products

20 competing products in Secondary Progressive Multiple Sclerosis

See all competitors
ProductCompanyStageHype Score
ASP7991 + Cinacalcet + PlaceboAstellas PharmaPhase 2
35
FycompaEisaiPre-clinical
26
FycompaEisaiPre-clinical
26
KHK7580 + KRN1493Kyowa KirinPhase 2/3
38
KHK7580Kyowa KirinPhase 1
29
KHK7580Kyowa KirinPhase 3
40
KHK7580Kyowa KirinPhase 3
40
Cinacalcet HClKyowa KirinApproved
43
KHK7580 + Cinacalcet HydrochlorideKyowa KirinPhase 3
40
Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493Kyowa KirinPhase 2
35
dirucotide + PlaceboEli LillyPhase 2/3
38
dirucotideEli LillyPhase 2/3
30
Paricalcitol + CalcitriolAbbViePre-clinical
18
paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placeboAbbViePhase 3
40
Paricalcitol + CalcifediolAbbVieApproved
43
Paricalcitol + Darbepoetin alfaAbbVieApproved
43
Birabresib Dose 20 mgMerckPhase 1
21
Remibrutinib (blinded) + Placebo + Remibrutinib (Open label)NovartisPhase 3
47
RanibizumabNovartisApproved
43
BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273NovartisApproved
43